We are live on ! Find out more
NXTC icon

NextCure
NXTC

17 hedge funds and large institutions have $5.03M invested in NextCure in 2025 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 11 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

11.72% less ownership

Funds ownership: 43.78% → 32.06% (-12%)

43% less funds holding

Funds holding: 30 → 17 (-13)

91% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 11

100% less capital inflows, than outflows

Capital inflows: $1.98K | Capital outflows: $883K

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 13

Holders
17
Holders Change
-13
Holders Change %
-43.33%
% of All Funds
0.22%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
1
Reduced
11
Closed
13
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Geode Capital Management
Geode Capital Management
Massachusetts
+$1.98K

Top Sellers

Rank Fund Capital Flow
1
Citigroup
Citigroup
New York
-$447K
2
Renaissance Technologies
Renaissance Technologies
New York
-$70.2K
3
Macquarie Group
Macquarie Group
Australia
-$69K
4
ADAR1 Capital Management
ADAR1 Capital Management
Texas
-$54.3K
5
Armistice Capital
Armistice Capital
New York
-$47.8K

NXTC Hedge Fund Activity: Q3 2025 in Review

17 of the 7,661 institutional investors tracked by Wall St. Rank reported a position in NextCure (NXTC) for Q3 2025, worth a combined $5.03M — down 11% from $5.65M a quarter earlier.

Sellers outnumbered buyers: 13 funds closed out of NXTC and 0 opened new positions — a net loss of 13 holders — while 11 trimmed existing stakes and 1 added.

The largest buyer was Geode Capital Management, adding an estimated $1.98K. The largest seller was Citigroup, cutting an estimated $447K.

  • 17 institutional investors held NextCure (NXTC) as of Q3 2025, down from 30 in Q2 2025.
  • Funds reported $5.03M of NextCure stock for Q3 2025, down 11% quarter-over-quarter.
  • 0 funds opened new NextCure positions in Q3 2025 and 13 closed out, a net change of -13 holders.
  • The largest NextCure buyer in Q3 2025 was Geode Capital Management, an estimated $1.98K added.
  • The largest NextCure seller in Q3 2025 was Citigroup, an estimated $447K sold.

Based on aggregated 13F filings for Q3 2025.